Law360, New York (November 23, 2004, 12:00 AM EST) -- Pfizer Inc. withheld crucial scientific data that might have influenced the patent review board's decision to grant the drug maker a second patent for Lipitor, attorneys for Indian generics maker Ranbaxy Laboratories Ltd. argued at the opening of the closely watched trial over patent rights to the blockbuster anti-cholesterol drug.
“Ranbaxy does not make this challenge wildly. We realize it is a serious charge,” said Darrell Olson, of the intellectual-property specialty firm Knobbe, Martens, Olson & Bear LLP of Irvine California, representing Ranbaxy.
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.